Provided is a compound represented by formula (IV) or a salt thereof, wherein the content of the compound represented by formula (I) is 350 ppm by mass or less.

Edits on 2 Oct, 2023

"Add patent inventor(s)"

Golden AI

edited on 2 Oct, 2023

Edits made to:

Infobox (+6 properties)

Infobox

Patent Inventor Names

Atsushi Akao0

Hirofumi Kuroda0

Taichi Abe0

Taiju Nakamura0

Yusuke Ayata0

Yusuke Miyashita0

Edits on 24 May, 2023

"Remove website redirecting to Patent Public Search front page"

Golden AI

edited on 24 May, 2023

Edits made to:

Infobox (-1 properties)

Infobox

Official Website

https://pdfpiw.uspto.gov/.piw?Docid=10259791

Edits on 28 Apr, 2023

"update citations for inverse infoboxes"

Golden AI

edited on 28 Apr, 2023

Infobox

Patent Citations Received

‌

US Patent 10822307 High-purity quinoline derivative and method for manufacturing same

Edits on 25 Apr, 2023

"update citations for inverse infoboxes"

Golden AI

edited on 25 Apr, 2023

Infobox

Patent Citations Received

‌

US Patent 11598776 Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds

Edits on 23 Mar, 2023

"update citations for inverse infoboxes"

Golden AI

edited on 23 Mar, 2023

Infobox

Patent Citations Received

‌

US Patent 11547705 Combination of a PD-1 antagonist and a VEGF-R/FGFR/RET tyrosine kinase inhibitor for treating cancer

Edits on 8 Mar, 2023

"update inverses"

Golden AI

edited on 8 Mar, 2023

Edits made to:

Infobox (+1 properties)

Infobox

Patent Citations Received

‌

US Patent 11598776 Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds

Edits on 11 Jan, 2023

"update inverses"

Golden AI

edited on 11 Jan, 2023

Edits made to:

Infobox (+1 properties)

Infobox

Patent Citations Received

‌

US Patent 11547705 Combination of a PD-1 antagonist and a VEGF-R/FGFR/RET tyrosine kinase inhibitor for treating cancer

Edits on 26 Sep, 2022

"update citations for inverse infoboxes"

Golden AI

edited on 26 Sep, 2022

Infobox

Patent Citations Received

‌

US Patent 11369623 Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor

Edits on 22 Sep, 2022

"update citations for inverse infoboxes"

Golden AI

edited on 22 Sep, 2022

Infobox

Patent Citations Received

‌

US Patent 10822307 High-purity quinoline derivative and method for manufacturing same

Edits on 29 Jun, 2022

"update inverses"

Golden AI

edited on 29 Jun, 2022

Edits made to:

Infobox (+1 properties)

Infobox

Patent citations received

‌

US Patent 11369623 Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor

Edits on 18 Jun, 2022

"Entity importer update"

Golden AI

edited on 18 Jun, 2022

Edits made to:

Infobox (+1 properties)

Infobox

Website URL

https://pdfpiw.uspto.gov/.piw?Docid=10259791

Edits on 7 Feb, 2022

"update inverses"

Golden AI

edited on 7 Feb, 2022

Edits made to:

Infobox (+1 properties)

Infobox

Patent citations received

‌

US Patent 10822307 High-purity quinoline derivative and method for manufacturing same

Edits on 25 Jan, 2022

"Created via: Entity Importer"

Golden AI

created this topic on 25 Jan, 2022

Edits made to:

Infobox (+9 properties)

‌

US Patent 10259791 High-purity quinoline derivative and method for manufacturing same

Infobox

Is a

Patent

Patent applicant

Eisai

Current assignee

Eisai

Patent jurisdiction

United States Patent and Trademark Office

Patent number

10259791

Date of patent

April 16, 2019

Patent application number

15503108

Date Filed

August 26, 2015

Patent primary examiner

‌

D Margaret M Seaman

Find more entities like US Patent 10259791 High-purity quinoline derivative and method for manufacturing same

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API